BC055324 Activators
Firrm, an acronym for FIGNL1 interacting regulator of recombination and mitosis, emerges as a critical player in cellular processes, particularly those associated with recombination and mitosis. With expression predominantly in the testis and thyroid gland, Firrm shares orthology with human C1orf112, suggesting conserved functions across species. The gene's predicted role as a regulator of recombination and mitosis implies its involvement in maintaining genomic stability and cell division. While direct activators of Firrm may not be readily identified, several chemicals indirectly influence its activity through modulation of specific signaling pathways. For instance, Palbociclib and Roscovitine, CDK inhibitors, indirectly activate Firrm by arresting the cell cycle, impacting its involvement in recombination and mitosis. Olaparib, a PARP inhibitor, directly activates Firrm by disrupting DNA repair mechanisms, highlighting the gene's role in maintaining genomic integrity. DNA-damaging agents like Bleomycin and Etoposide directly activate Firrm by inducing DNA damage, influencing recombination processes crucial for genomic stability.
Additionally, Firrm responds to topoisomerase inhibitors like Doxorubicin and Camptothecin, which induce DNA damage and alter DNA structure, affecting its role in recombination and mitosis. Inhibition of ATR by VX-970 and DNA-PK by NU7441 indirectly activates Firrm by disrupting cell cycle checkpoints and DNA repair processes, respectively. These findings emphasize Firrm's intricate involvement in maintaining genomic stability and ensuring proper cell division. In summary, Firrm stands as a key regulator in cellular processes, particularly recombination and mitosis. Its activation mechanisms involve responses to various chemicals that either directly induce DNA damage or indirectly modulate cell cycle checkpoints and DNA repair processes. Understanding Firrm's role contributes to the broader comprehension of genomic stability and cell division, providing insights into potential avenues for further research in cellular biology and molecular medicine.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
PD 0332991, a CDK4/6 inhibitor, indirectly activates Firrm by arresting the cell cycle. Inhibition of CDK4/6 influences cellular proliferation, impacting Firrm's involvement in recombination and mitosis. Palbociclib's role in cell cycle regulation establishes an indirect activation mechanism for Firrm through its impact on cell cycle progression and associated cellular processes. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
Olaparib, a PARP inhibitor, directly activates Firrm by disrupting DNA repair mechanisms. Inhibition of PARP influences recombination processes, affecting Firrm's role in DNA repair and mitosis. Olaparib's role in DNA repair inhibition provides a direct activation mechanism for Firrm through its impact on DNA repair pathways and associated cellular processes. | ||||||
Bleomycin | 11056-06-7 | sc-507293 | 5 mg | $270.00 | 5 | |
Bleomycin, a DNA-damaging agent, directly activates Firrm by inducing DNA damage. DNA damage stimulates recombination processes, influencing Firrm's role in recombination and mitosis. Bleomycin's impact on DNA integrity provides a direct activation mechanism for Firrm through its induction of DNA damage and subsequent effects on recombination and mitosis. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
AZD7762, a CHK1 inhibitor, indirectly activates Firrm by disrupting cell cycle checkpoints. Inhibition of CHK1 influences cell cycle progression, impacting Firrm's involvement in recombination and mitosis. AZD7762's role in cell cycle regulation establishes an indirect activation mechanism for Firrm through its impact on checkpoint regulation and associated cellular processes. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Etoposide, a topoisomerase II inhibitor, directly activates Firrm by inducing DNA damage. Inhibition of topoisomerase II influences DNA integrity, affecting Firrm's role in recombination and mitosis. Etoposide's impact on DNA structure provides a direct activation mechanism for Firrm through its induction of DNA damage and subsequent effects on recombination and mitosis. | ||||||
NU 7441 | 503468-95-9 | sc-208107 | 5 mg | $350.00 | 10 | |
NU7441, a DNA-PK inhibitor, indirectly activates Firrm by disrupting DNA repair processes. Inhibition of DNA-PK influences DNA repair mechanisms, impacting Firrm's involvement in recombination and mitosis. NU7441's role in DNA repair inhibition establishes an indirect activation mechanism for Firrm through its impact on DNA repair pathways and associated cellular processes. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Mitomycin C, a DNA cross-linking agent, directly activates Firrm by inducing DNA damage. DNA cross-linking influences recombination processes, affecting Firrm's role in recombination and mitosis. Mitomycin C's impact on DNA structure provides a direct activation mechanism for Firrm through its induction of DNA damage and subsequent effects on recombination and mitosis. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine, a CDK inhibitor, indirectly activates Firrm by arresting the cell cycle. Inhibition of CDKs influences cellular proliferation, impacting Firrm's involvement in recombination and mitosis. Roscovitine's role in cell cycle regulation establishes an indirect activation mechanism for Firrm through its impact on cell cycle progression and associated cellular processes. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Camptothecin, a topoisomerase I inhibitor, directly activates Firrm by inducing DNA damage. Inhibition of topoisomerase I influences DNA integrity, affecting Firrm's role in recombination and mitosis. Camptothecin's impact on DNA structure provides a direct activation mechanism for Firrm through its induction of DNA damage and subsequent effects on recombination and mitosis. | ||||||
Aphidicolin | 38966-21-1 | sc-201535 sc-201535A sc-201535B | 1 mg 5 mg 25 mg | $82.00 $300.00 $1082.00 | 30 | |
Aphidicolin, a DNA polymerase inhibitor, indirectly activates Firrm by disrupting DNA replication. Inhibition of DNA polymerase influences DNA synthesis, impacting Firrm's involvement in recombination and mitosis. Aphidicolin's role in DNA replication inhibition establishes an indirect activation mechanism for Firrm through its impact on DNA synthesis and associated cellular processes. | ||||||